Skip to content
Screener

Tango Therapeutics TNGX Unrealized Losses on Investments (Before Tax)

Unrealized Losses on Investments (Before Tax) at other companies

Amgen logo
AmgenAMGN
$0—
Gilead Sciences logo
Gilead SciencesGILD
$1M—
Exelixis logo
ExelixisEXEL
$3.06M+349%

Other financials

Income statement

See full
Revenue--100%
Operating income-$48.8M-14.7%
Net income-$45.5M-14.1%
EPS (diluted)-$0.32+11.1%

Balance sheet

See full
Cash & equivalents$160.0M+162%
Total debt$32.8M-11.3%
Total equity$391.5M+135%
Total assets$435.8M+58.9%

Cash flow

See full
Operating cash flow-$44.4M-6.4%
CapEx-$2.0K-104%
Free cash flow-$44.4M-6.3%

Valuation

See full
Market cap$4.51B+532%
Enterprise value$4.38B+520%
P/S79.1×+49.7×

Profitability

See full
Operating margin-206.2%-61.0pp
Net margin-188.2%-55.4pp
FCF margin-250.1%-49.4pp

Returns & leverage

See full
Return on equity-38.4%-10.5pp
Debt / equity0.1×-0.1×
Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.

The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-221656
Line itemAmortized CostGross Unrealized GainsGross Unrealized LossFair Value
Marketable debt securities:
U.S. Treasury bills$99,509$7$(15)$99,501
U.S. government agency bonds122,61712(119)122,510
$222,126$19$(134)$222,011

Item 1. Financial Statements.

FAQ

What is Tango Therapeutics's unrealized losses on investments (before tax)?
Tango Therapeutics (TNGX) reported unrealized losses on investments (before tax) of $134K in Q1 2026.
How has Tango Therapeutics's unrealized losses on investments (before tax) changed year-over-year?
Tango Therapeutics's unrealized losses on investments (before tax) increased by 396.3% year-over-year, from $27K to $134K.
What is the long-term trend for Tango Therapeutics's unrealized losses on investments (before tax)?
Over 4 years (2021 to 2025), Tango Therapeutics's unrealized losses on investments (before tax) has grown at a -100.0% compound annual growth rate (CAGR), from $766K to $0.

Ask your AI about Tango Therapeutics's unrealized losses on investments (before tax).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude